- Illumina’s fourth quarter revenue reported at $1.10 billion, surpassing the estimate of $1.09 billion.
- Product revenue for the quarter reached $939 million.
- Service and other revenue totaled $165 million for the same period.
- The company’s adjusted gross margin was 67.4%, which was slightly below the estimated 68.8%.
- Illumina reported cash and cash equivalents at $1.13 billion, falling short of the estimated $1.33 billion.
- For fiscal year 2025, Core Illumina’s constant currency revenue growth is expected to be in the low single digits.
- Projected reported revenue for fiscal year 2025 is between $4.28 billion and $4.4 billion.
- Non-GAAP operating margin for 2025 is expected to be approximately 23%.
- Non-GAAP diluted EPS is anticipated to range from $4.50 to $4.65.
- The company has 14 buy ratings, 14 hold ratings, and 1 sell rating from analysts.
Illumina Inc on Smartkarma
Analyst coverage of Illumina Inc on Smartkarma reveals insights from Baptista Research. In one report titled “Illumina Inc.: These Are The 3 Biggest Challenges In Its Path! – Major Drivers,” the analysis highlights a mixed third-quarter performance for Illumina in 2024. The company reported $1.1 billion in quarterly revenue, meeting expectations but showing a 2% decrease year-over-year. This decline was attributed to reduced instrument sales due to comparisons with the NovaSeq X series launch and global capital constraints.
Another report by Baptista Research, “Illumina Inc.: The Tale Of Global Market Penetration and Expansion! – Major Drivers,” discusses Illumina’s revenue results in the second quarter of 2024. Despite challenges like extended sales cycles and global economic pressures impacting equipment orders, Illumina exceeded revenue expectations. Consumption of sequencing consumables, driven by NovaSeq X Plus, saw a significant increase, indicating potential future growth amidst the company’s strategic priorities.
A look at Illumina Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Illumina Inc has a mix of ratings across different factors. The company scores highest in Momentum with a score of 4, indicating strong positive price momentum. This suggests that investors have been showing increased interest and confidence in Illumina’s future prospects. However, on the flip side, Illumina scores lower in Value, Dividend, Growth, and Resilience, with ratings of 2 across these factors. While this may raise concerns for some investors looking for stable returns or value investments, the company’s strong momentum could indicate a positive market sentiment and potential growth opportunities in the future.
Illumina, Inc. is a company that specializes in developing, manufacturing, and marketing integrated systems for genetic analysis on a large scale. Their products and services cater to various markets including sequencing, genotyping, and gene expression for research centers, pharmaceutical firms, academic institutions, and biotech companies. With a mixed bag of Smartkarma Smart Scores, Illumina’s high momentum score may hint at a promising future despite lower ratings in other areas such as value, dividend, growth, and resilience. Investors may want to keep an eye on how these factors evolve to make informed decisions about the long-term outlook of Illumina Inc.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
